argenx Acquires Forte Biosciences in $2.2 Billion Cash Deal
argenx SE has agreed to acquire Forte Biosciences for approximately $2.2 billion, offering $77 per share in cash. The deal will expand argenx's immunology portfolio by adding FB102, a first-in-class anti-CD122 antibody developed by Forte. The acquisition is expected to strengthen argenx’s position in the biopharmaceutical sector and enhance its pipeline of innovative therapies targeting immune-related diseases. The transaction highlights growing interest in advanced immunology treatments among pharmaceutical companies.
